Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Core Insights - Clearside Biomedical, Inc. is advancing the treatment of multiple macular diseases through its suprachoroidal drug delivery platform, highlighted by positive clinical data for its lead program, CLS-AX [1][2] Presentation Highlights - Six presentations at the ARVO 2025 Meeting showcased the efficacy and safety of CLS-AX, particularly its ability to maintain stable best corrected visual acuity (BCVA) while reducing injection frequency in patients with neovascular age-related macular degeneration (nAMD) [1][5] - The Phase 2b ODYSSEY trial demonstrated that CLS-AX offers durability and therapeutic potential, achieving its primary outcome [5] - The suprachoroidal delivery method is positioned as a transformative approach for treating retinal diseases, with Clearside recognized as a leader in this field [2][5] Technological Innovations - Clearside has developed a machine learning algorithm for imaging the suprachoroidal space (SCS) post-drug delivery, enhancing patient data evaluation [5] - The SCS Microinjector, designed for targeted drug delivery, has completed over 15,000 injections, establishing a clinically validated training program [5][9] Product Development - CLS-AX is a proprietary suspension of axitinib, a tyrosine kinase inhibitor, which has shown a positive safety profile in clinical trials and aims to provide prolonged and targeted delivery for retinal diseases [8][10] - The company is also planning a Phase 3 trial for CLS-AX and evaluating other small molecules for potential long-acting treatments [10]